# US 2017/0253629 A1 · 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253629 A1
- Document ID: US20170253629A1
- Status: Published application
- Kind: A1
- Application number: 15/518,527
- Filed: 2015-11-27
- Published: 2017-09-07
- Earliest claimed: 2014-11-28
- Assignees: NuCana BioMed Limited
- Applicants: NuCana Biomed Limited
- Inventors: Hugh Griffith; Christopher McGuigan; Velentina Ferrari; Michaela Serpi; Carmen Jimenez Antunez
- Web page: https://patentgrep.com/patent/US20170253629A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07H 19/20: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A61P 35/02: specific for leukemia
- C07H 19/16: Purine radicals
- C07H 19/173: with 2-deoxyribosyl as the saccharide radical
- C07H 19/207: the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Disclosed are chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and pharmaceutical compositions comprising the compounds. The compounds may, in particular, be useful in the treatment of leukaemia, lymphoma and/or solid tumours in homo sapiens. The compounds are derivatives of cordycepin (3′-deoxyadenosine) having a 2′ and/or 5′-amino-acid ester phosphoramidate moiety.

## Claims

### Claim 1

A compound of formula (Ib):
wherein
W1 and W2 are each independently selected from the group consisting of —P(═O)(U)(V) and H, with the proviso that at least one of W1 and W2 is —P(═O)(U)(V),
where U and V, independently for each of W1 and W2, are selected from the group consisting of
(a) U is —OAr and V is —NR4—CR1R2—C(═O)OR3,
where Ar is selected from the group consisting of C6-30aryl and 5-30-membered heteroaryl, each of which is optionally substituted;
each of R1 and R2 is independently selected from H, and the group consisting of C1-20alkyl, C6arylC1-6alkyl, C2-20alkenyl, C1-20alkoxy, C1-20alkoxyC1-20alkyl, C1-20alkoxyC6aryl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, C6-30aryloxy and 5-20-membered heterocyclyl, any of which is optionally substituted;
R3 is selected from H, and the group consisting of C1-20alkyl, C6-30arylC1-20alkyl, C2-20alkenyl, C1-20alkoxyC1-20alkyl, C1-20alkoxyC6-30aryl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, and 5-20-membered heterocyclyl, any of which is optionally substituted;
R4 is selected from H, and the group consisting of C1-20alkyl, C6-30arylC1-20alkyl, C2-20alkenyl, C1-20alkoxy, C1-20alkoxyC1-20alkyl, C1-20alkoxyC6-30aryl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, C6-30aryloxy and 5-20-membered heterocyclyl, any of which is optionally substituted;
and
(b) each of U and V is selected independently from —NR5R6,
where R5 is selected from the group consisting of H and C1-6alkyl and R6 is —CR7R8CO2R9, where R7 and R8 are selected independently from the group consisting of the side chains, including H, of naturally occurring alpha amino acids and R9 is selected from H, and the group consisting of C1-20alkyl, C6-30arylC1-20alkyl-, C2-20alkenyl, C1-20alkoxyC1-20alkyl, C1-20alkoxyC6-30aryl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, and 5-20-membered heterocyclyl, any of which is optionally substituted; or
R5 and R6 together with the N atom to which they are attached form a ring moiety comprising 5; to 8 ring atoms;
X is selected from the group consisting of
NR12R13, where each of R12 and R13 is independently selected from the group consisting of H and C1-6alkyl; and
—SR14, where R14 is selected from the group consisting of H and C1-6alkyl;
Z is independently selected from the group consisting of H, OH, F, Cl, Br, I, C1-6alkyl, —N12R13, and —SR14 where R14 is selected from the group consisting of H and C1-6alkyl; and
Y is selected from the group consisting of H, OH, F, Cl, Br, I, —OC1-6alkyl, C1-6alkyl, C2-8alkynyl, —N15R16 where each of R15 and R16 is independently selected from H and C1-6alkyl, and —SR17 where R17 is selected from the group consisting of H and C1-6alkyl,
or a pharmaceutically acceptable salt, ester, salt of an ester, solvate or prodrug of the compound of formula (Ib).

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is represented by formula (II):
wherein X is NR12R13.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein Ar is selected from the group consisting of phenyl and napthyl.

### Claim 4 (depends on 3)

The compound according to claim 3, wherein Ar is unsubstituted.

### Claim 5 (depends on 3)

The compound according to claim 3, wherein Ar is substituted with one, two, three, four or five substituents selected from the group consisting of halo, C1-C4-alkyl, C1-C4-alkoxy, nitro, and cyano.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R2 is C1-C4-alkyl.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein R2 is methyl.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein the C atom bearing R1 and R2 has the absolute configuration of L-alanine.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein R3 is selected from the group consisting of benzyl and unsubstituted C1-20alkyl.

### Claim 10 (depends on 9)

The compound according to claim 9, wherein R3 is selected from the group consisting of benzyl, unsubstituted methyl and unsubstituted n-pentyl.

### Claim 11 (depends on 10)

The compound according to claim 10, wherein R3 is benzyl.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein X is NH2.

### Claim 13 (depends on 1)

The compound according to claim 1, wherein Y is H.

### Claim 14 (depends on 1)

The compound according to claim 1, wherein Z is H.

### Claim 15 (depends on 1)

The compound according to claim 1, wherein Z is F.

### Claim 16 (depends on 1)

The compound according to claim 1, wherein Z is C1.

### Claim 17 (depends on 1)

The compound according to claim 1, wherein Z is OMe.

### Claim 18 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:
(2S)-Benzyl 2-(((((2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)amino)propanoate;
Benzyl 2-(((((2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)acetate;
(2S)-Pentyl 2-(((((2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)amino)-4-methylpentanoate;
Methyl 2-(((((2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)amino)-2-methylpropanoate;
(2S)-Benzyl 2-(((((2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)(2-(3-ethoxy-3-oxopropyl)phenoxy)phosphoryl)amino)propanoate;
(2S)-Benzyl 2-(((((2R,3R,5S)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)(phenoxy)phosphoryl)amino)propanoate;
Benzyl 2-(((((2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-((((1-(benzyloxy)-1-oxopropan-2-yl)amino)(phenoxy)phosphoryl)oxy)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate;
(2S)-Benzyl 2-(((((2R,3R,5S)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)(naphthalen-1-yloxy)phophoryl)amino)proponate;
Benzyl 2-[({[5-(6-amino-9H-purin-9-yl)-4-hydroxyoxolan-2-yl]methoxy}({[1-(benzyloxy)-1-oxopropan-2-yl]amino})phosphoryl)amino]propanoate;
(2S)-Benzyl 2-((((2S,4R,5R)-5-(6-amino-2-methoxy-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)propanoate;
(2S)-Benzyl 2-((((2S,4R,5R)-5-(6-amino-2-methoxy-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;
(2S)-Benzyl 2-(((((2S,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate;
(2S)-Hexyl 2-(((((2S,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate;
(2R)-Benzyl 2-((((2S,4R,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)propanoate;
3′-Deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)] phosphate;
2-O-Methyl-3′-deoxyadenosine-5′-O-[1-naphthyl(1-pentyloxy-L-leucinyl)] phosphate;
2-O-Methyl-3′-deoxyadenosine-5′-O-[phenyl(1-hexyloxy-L-alaninyl)] phosphate;
2-Fluoro-3′-deoxyadenosine-5′-O-[1-naphthyl(benzyloxy-L-alaninyl)] phosphate;
2-Fluoro-3′-deoxyadenosine-5′-O-[1-naphthyl(1-pentyloxy-L-leucinyl)] phosphate;
2-Chloro-3′deoxyadenosine 5′-O-[1-phenyl (2,2-dimethylpropoxy-L-alanine)] phosphate;
2-Chloro-3′deoxyadenosine 5′-O-[1-naphtyl (2,2-dimethylpropoxy-L-alanine)] phosphate;
2-Chloro-3′deoxyadenosine 5′-O-[1-phenyl (ethoxy-L-alanine)] phosphate; and
(2S)-isopropyl-2-(((((2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate.

### Claim at position 19

19-24. (canceled)

### Claim 25

A method of prophylaxis or treatment of cancer, comprising administering to a patient in need thereof an effective dose of a compound of formula (Ib):
wherein
W1 and W2 are each independently selected from the group consisting of —P(═O)(U)(V) and H, with the proviso that at least one of W1 and W2 is —P(═O)(U)(V),
where U and V, independently for each of W1 and W2, are selected from the group consisting of
(a) U is —OAr and V is —NR4—CR1R2—C(═O)OR3,
where Ar is selected from the group consisting of C6-30aryl and 5-30-membered heteroaryl, each of which is optionally substituted;
each of R1 and R2 is independently selected from H, and the group consisting of C1-20alkyl, C6arylC1-6alkyl, C2-20alkenyl, C1-20alkoxy, C1-20alkoxyC1-20alkyl, C1-20alkoxyC6aryl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, C6-30aryloxy and 5-20-membered heterocyclyl, any of which is optionally substituted;
R3 is selected from H, and the group consisting of C1-20alkyl, C6-30arylC1-20alkyl, C2-20alkenyl, C1-20alkoxyC1-20alkyl, C1-20alkoxyC6-30aryl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, and 5-20-membered heterocyclyl, any of which is optionally substituted;
R4 is selected from H, and the group consisting of C1-20alkyl, C6-30arylC1-20alkyl, C2-20alkenyl, C1-20alkoxy, C1-20alkoxyC1-20alkyl, C1-20alkoxyC6-30aryl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, C6-30aryloxy and 5-20-membered heterocyclyl, any of which is optionally substituted;
and
(b) each of U and V is selected independently from —NR5R6,
where R5 is selected from the group consisting of H and C1-6alkyl and R6 is —CR7R8CO2R9, where R7 and R8 are selected independently from the group consisting of the side chains, including H, of naturally occurring alpha amino acids and R9 is selected from H, and the group consisting of C1-20alkyl, C6-30arylC1-20alkyl-, C2-20alkenyl, C1-20alkoxyC1-20alkyl, C1-20alkoxyC6-30aryl, C2-20alkynyl, C3-20cycloalkyl, C6-30aryl, and 5-20-membered heterocyclyl, any of which is optionally substituted; or
R5 and R6 together with the N atom to which they are attached form a ring moiety comprising 5 to 8 ring atoms;
X is selected from the group consisting of
NR12R13 where each of R12 and R13 is independently selected from the group consisting of H and C1-6alkyl; and
—SR14 where R14 is selected from the group consisting of H and C1-6alkyl;
Z is independently selected from the group consisting of H, OH, F, Cl, Br, I, C1-6alkyl, —N12R13, and —SR14 where R14 is selected from the group consisting of H and C1-6alkyl; and
Y is selected from the group consisting of H, OH, F, Cl, Br, I, —OC1-6alkyl, C1-6alkyl, C2-8alkynyl, —N15R16 where each of R15 and R16 is independently selected from H and C1-6alkyl, and —SR17 where R17 is selected from the group consisting of H and C1-6alkyl,
or a pharmaceutically acceptable salt, ester, salt of an ester, solvate or prodrug of the compound of formula (Ib).

### Claim 26 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1; and a pharmaceutically acceptable excipient.

### Claim 27 (depends on 25)

The method according to claim 25, wherein the cancer is selected from the group consisting of leukaemia, lymphoma, multiple myeloma, lung cancer, liver cancer, breast cancer, bladder cancer, prostate cancer, head and neck cancer, neuroblastoma, sarcoma, thyroid carcinoma, skin cancer, oral squamous cell carcinoma, urinary bladder cancer, Leydig cell tumour, biliary cancer, such as cholangiocarcinoma or bile duct cancer, pancreatic cancer, colon cancer, colorectal cancer and gynaecological cancers.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the cancer is leukaemia or lymphoma.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the cancer is leukaemia; and the leukaemia is selected from the group consisting of acute lymphoblastic leukaemia, acute myelogenous leukaemia, acute promyelocytic leukaemia, acute lymphocytic leukaemia, chronic myelogenous leukaemia, chronic lymphocytic leukaemia, monoblastic leukaemia, hairy cell leukaemia, Hodgkin lymphoma and non-Hodgkin lymphoma.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the leukaemia is acute lymphoblastic leukaemia.
